KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Deferred Revenue (2016 - 2017)

Acadia Pharmaceuticals has reported Current Deferred Revenue over the past 7 years, most recently at $4.1 million for Q1 2017.

  • Quarterly results put Current Deferred Revenue at $4.1 million for Q1 2017, changed N/A from a year ago — trailing twelve months through Mar 2017 was $4.1 million (changed N/A YoY), and the annual figure for FY2016 was $2.6 million, changed.
  • Current Deferred Revenue for Q1 2017 was $4.1 million at Acadia Pharmaceuticals, up from $2.6 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ACAD hit a ceiling of $4.1 million in Q1 2017 and a floor of $15000.0 in Q3 2014.
  • Median Current Deferred Revenue over the past 4 years was $111000.0 (2013), compared with a mean of $876090.9.
  • Peak annual rise in Current Deferred Revenue hit 69.92% in 2013, while the deepest fall reached 87.33% in 2013.
  • Acadia Pharmaceuticals' Current Deferred Revenue stood at $55000.0 in 2013, then tumbled by 72.73% to $15000.0 in 2014, then surged by 17526.67% to $2.6 million in 2016, then surged by 56.28% to $4.1 million in 2017.
  • The last three reported values for Current Deferred Revenue were $4.1 million (Q1 2017), $2.6 million (Q4 2016), and $1.9 million (Q3 2016) per Business Quant data.